| FRANCE | WP3 | |||
| Organization | INSERM | |||
| Name of cohort | EPICOV | |||
| Referring partner | INSERM | |||
| Cohort Information | Country(-ies), cities, regions or centers involved | France | ||
| Time of data collection | 05/2020 | 03/2023 | ||
| Enrolment | Inactive | |||
| Study setting | Multi-centers | |||
| Population | Age | Adolescents,Adults,Elderly | ||
| Type | Retrospective | |||
| Total number of patients | 107759 | |||
| Data collection | Clinical data | True | ||
| Serological data | True | |||
| Genetic data | False | |||
| Sample collection | True | |||
| Sample collected | Whole blood | No | ||
| PBMC | No | |||
| Dry-spot blood | Yes | |||
| Plasma | No | |||
| Serum | No | |||
| Stool | No | |||
| NP swabs | No | |||
| Other | None | |||
| Description | The EpiCov study is a French, prospective, random population-based, socio-epidemiological cohort set up in April 2020. Individuals aged 15 years or older living in France (excluding people living in residences for elderly and living in jail) were randomly selected from the national Fichiers démographiques sur les logements et les individus (FIDELI) administrative sampling frame. Among the 134 391 people who responded the first round in May-June 2020, 107 759 responded to the second round in October-December 2020, and among them 85 074 responded to the third round in June-August 2021. Data were collected through computer-assisted-web interviews (CAWI) or computer-assisted-telephone interviews (CATI). Home self-sampling on dried blood were collected for central Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2) Immunoglobulin G (IgG) antibodies testing during the first and second rounds. Home samples on DBS for detection IgG and neutralizing antibodies were collected in a random sub-sample of 12114 for 1st round of the EPICOV survey (May) and all respondents in November 2020. Purpose: provide national and regional estimate of sero-prevalence of SARS-CoV-2 infection and to analyze relations between living conditions and the dynamics of the epidemic. Additional questions: possible to add questions depending on respective agenda of EPICOV and ORCHESTRA. NB: multi-center is not adequate for our study. Consider it non applicable. | |||
| Publications |
- Serological response after SARS-CoV2 vaccination in healthcare workers: a multicenter study [La Medicina del Lavoro] - Risk and severity of SARS-CoV-2 infection in breast cancer patients undergoing a structured infection screening program at the University and Hospital Trust of Verona [Annals of Oncology] - Trends in social exposure to SARS-Cov-2 in France. Evidence from the national socio-epidemiological cohort EPICOV [PLoS ONE] - Predictors of clinical evolution of SARS-CoV-2 infection in hematological patients: a systematic review and meta-analysis [Hematological Oncology] - Determinants of Anti-S Immune Response at 9 Months after COVID-19 Vaccination in a Multicentric European Cohort of Healthcare WorkersORCHESTRA Project [Viruses] - Temporal trends of COVID-19 antibodies in vaccinated healthcare workers undergoing repeated serological sampling: An individual-level analysis within 13 months in the ORCHESTRA cohort [Frontiers Immunology] - ORCHESTRA: Connecting European Cohorts to Increase Common and Effective Response to SARS-CoV-2 [Cineca HPC Report 2021-2022] - Relationship Between Immune Response to Severe Acute Respiratory Syndrome Coronavirus 2 Vaccines and Development of Breakthrough Infection in Solid Organ Transplant Recipients: The CONTRAST Cohort [Clinical Infectious Diseases] - Host immunological responses facilitate development of SARS-CoV-2 mutations in patients receiving monoclonal antibody treatments [The journal of clinical investigation] - Higher risk, higher protection: COVID-19 risk among immigrants in Franceresults from the population-based EpiCov survey [European Journal of Public Health] | |||